In Vitro Radiosensitization of Esophageal Cancer Cells with the Aminopeptidase Inhibitor CHR-2797

With the increased incidence of esophageal cancer, chemoradiotherapy continues to play an important role in the management of this disease. Developing potent radiosensitizers is therefore critical for improving outcomes. The use of drugs that have already undergone clinical testing is an appealing a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Radiation research Ročník 184; číslo 3; s. 259 - 265
Hlavní autoři: Anbalagan, Selvakumar, Biasoli, Deborah, Leszczynska, Katarzyna B., Mukherjee, Somnath, Hammond, Ester M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States The Radiation Research Society 01.09.2015
Radiation Research Society
Allen Press Inc
Témata:
Aminopeptidases - antagonists & inhibitors
Biotechnology
Cancer
Cell Line, Tumor
Deoxyribonucleic acid
DNA
Esophageal Neoplasms - pathology
Esophageal Neoplasms - radiotherapy
Glycine - analogs & derivatives
Glycine - pharmacology
Humans
Hydroxamic Acids - pharmacology
In vitro testing
Inhibitors
Management
Radiation-Sensitizing Agents - pharmacology
Radiosensitizers
REGULAR ARTICLE
REGULAR ARTICLES
Side effects
ISSN:0033-7587, 1938-5404, 1938-5404
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:With the increased incidence of esophageal cancer, chemoradiotherapy continues to play an important role in the management of this disease. Developing potent radiosensitizers is therefore critical for improving outcomes. The use of drugs that have already undergone clinical testing is an appealing approach once the side effects and tolerated doses are established. Here, we demonstrate that the aminopeptidase inhibitor, CHR-2797/tosedostat, increases the radiosensitivity of esophageal cancer cell lines (FLO-1 and OE21) in vitro in both normoxic and physiologically relevant low oxygen conditions. To our knowledge, the effective combination of CHR-2797 with radiation exposure has not been reported previously in any cancer cell type. The mechanism of increased radiosensitivity was not dependent on the induction of DNA damage or DNA repair kinetics. Our data support the need for further preclinical testing of CHR-2797 in combination with radiotherapy for the treatment of esophageal cancer.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0033-7587
1938-5404
1938-5404
DOI:10.1667/RR14150.1